Nov ,2023 Aponermin for Injection (Brand Name:SHAAITE) of Wuhan HITECK biopharmaceutical Co., Ltd. is approved for marketing by China NMPA, which is used in combination with thalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory Multiple Myeloma after two or more systemic therapies.
Aponermin for Injection is a recombinant allosteric human tumor necrosis factor-related apoptosis-inducing ligand (Circularly Permuted TRAIL, referred to as CPT). It is currently the only DR4/DR5 agonist approved for marketing in the world. And the core technologies have obtained patent protection in many countries around the world. CPT triggers intracellular caspase cascade reactions through the exogenous apoptosis pathway, thereby exerting anti-tumor effects. Foreign drugs with the same target are still in clinical phase I or phase II. The launch of CPT will provide a new drug treatment path for cancer patients.
About Multiple myeloma (MM)
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.https://medlineplus.gov/multiplemyeloma.html
Patients with newly diagnosed patients with multiple myeloma continues to rise every year around the world, making it the second most common malignant tumor of the hematology system. Although great progress has been made in the research and development of new drugs for multiple myeloma in the past decade, multiple myeloma is still an incurable hematological malignant disease, and almost all patients will develop resistance to currently available anti-myeloma drugs. Drug properties, leading to disease recurrence. As the number of relapses increases, the prognosis of this patient group becomes worse and worse, and treatment becomes more and more difficult, which makes it more difficult to obtain remission and the duration of remission maintenance becomes shorter and shorter. Therefore, there is still an urgent need for more effective treatments for relapsed or refractory multiple myeloma.
About Wuhan HITECK biopharmaceutical Co., Ltd
Wuhan HITECK biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise with the goal of building an excellent innovative biopharmaceutical enterprise in China. The company is based on the R & D and production of drugs in the fields of nervous system and oncology. At present, a national class I biological new drug, mouse nerve growth factor for injection (Jinlujie), and a class I genetic engineering biological new drug, recombinant mutant human tumor necrosis factor related apoptosis inducing ligand (CPT), have been put on the market for sale. Phase III clinical blinding work has been completed and the application for production approval is in the preparation stagehttps://www.hiteck.com.cn/profile.html.